"Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," Glenmark Pharmaceuticals Senior Vice President and Head - Asia, Russia and CIS region Csaba Kantor said.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment